Drug Profile
TTP 814
Alternative Names: TTP814Latest Information Update: 22 Sep 2015
Price :
$50
*
At a glance
- Originator TransTech Pharma
- Developer vTv Therapeutics
- Class Antihyperglycaemics
- Mechanism of Action Protein-tyrosine-phosphatase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Type 2 diabetes mellitus
Most Recent Events
- 22 Sep 2015 Discontinued - Phase-I/II for Type-2 diabetes mellitus in USA (PO)
- 11 Jun 2010 Phase-I/II clinical trials in Type-2 diabetes mellitus in USA (PO)
- 27 Jul 2004 Preclinical trials in Type-2 diabetes mellitus in USA (PO)